Invivyd, Inc. (NASDAQ:IVVD – Get Free Report) insider Robert Allen III sold 17,043 shares of the company’s stock in a transaction dated Tuesday, August 18th. The shares were sold at an average price of $0.84, for a total value of $14,316.12. Following the completion of the sale, the insider owned 178,765 shares of the company’s stock, valued at $150,162.60. This represents a 8.70% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.
Invivyd Trading Up 17.2%
NASDAQ:IVVD opened at $0.87 on Wednesday. Invivyd, Inc. has a 1-year low of $0.48 and a 1-year high of $3.07. The firm has a market capitalization of $255.75 million, a price-to-earnings ratio of -2.63 and a beta of 0.71. The business’s 50-day moving average price is $0.77 and its two-hundred day moving average price is $1.23.
Invivyd (NASDAQ:IVVD – Get Free Report) last posted its earnings results on Thursday, August 13th. The company reported ($0.14) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $14.29 million for the quarter, compared to analyst estimates of $14.40 million. Invivyd had a negative return on equity of 59.73% and a negative net margin of 183.90%. Sell-side analysts predict that Invivyd, Inc. will post -0.52 earnings per share for the current year.
Analyst Ratings Changes
Check Out Our Latest Stock Report on IVVD
Hedge Funds Weigh In On Invivyd
Several institutional investors have recently modified their holdings of the business. Jupiter Topco LLC acquired a new position in shares of Invivyd in the 2nd quarter valued at approximately $30,048,000. Janus Henderson Group PLC raised its holdings in Invivyd by 1.7% during the 1st quarter. Janus Henderson Group PLC now owns 33,094,330 shares of the company’s stock worth $42,857,000 after buying an additional 551,188 shares during the period. Perceptive Advisors LLC acquired a new stake in Invivyd during the 4th quarter worth approximately $53,809,000. BVF Inc. IL bought a new position in Invivyd in the fourth quarter valued at approximately $48,227,000. Finally, RA Capital Management L.P. bought a new position in Invivyd in the third quarter valued at approximately $18,831,000. Institutional investors own 70.36% of the company’s stock.
More Invivyd News
Here are the key news stories impacting Invivyd this week:
- Neutral Sentiment: Robert D. Allen III, Jill Andersen, CFO William E. Duke, Julie Green, and Timothy Edward Lee each sold shares at prices of approximately $0.72 or $0.84. The sales reduced each insider’s direct holdings by roughly 9% to 11%. SEC insider transaction filing
- Neutral Sentiment: The filings state that the transactions were made to cover tax-withholding obligations tied to the vesting of equity awards. Because the sales were not described as discretionary reductions or based on a negative outlook, they are less concerning than open-market sales intended to exit positions. SEC insider transaction filing
- Negative Sentiment: The concentration of sales by multiple insiders may nevertheless create a modest overhang for Invivyd stock, particularly given the company’s small market capitalization and recent elevated trading volume. However, the disclosed tax-related purpose limits the bearish signal.
Invivyd Company Profile
Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering. Its pipeline includes PEMGRADA (pemivibart) injection, a half-life extended investigational monoclonal antibody (mAb) for the prevention of COVID-19 in adults and adolescents; VYD2311, an mAb candidate which is in preclinical studies for the prevention or treatment for COVID-19; and adintrvimab, that is in phase 3 clinical trials for the prevention or treatment of COVID-19.
Featured Stories
- Five stocks we like better than Invivyd
- The AI Boom Is Turning This Cable Maker Into a Stock to Watch
- A Star Investor Just Trimmed Amazon—Here’s What It means
- Wendy’s Deal Buzz May Give Fast-Food Investors a New Reason to Look
- Home Depot Analysts See a Path to $375 and Beyond
Receive News & Ratings for Invivyd Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Invivyd and related companies with MarketBeat.com's FREE daily email newsletter.
